Adis
OPEN ACCESS
PEER-REVIEWED INFOGRAPHIC

Perspectives on subcutaneous infliximab for rheumatic diseases and inflammatory bowel disease: before, during, and after the COVID-19 era

Stefan Schreiber, Shomron Ben-Horin, Rieke Alten, René Westhovens, Laurent Peyrin-Biroulet, Silvio Danese, Toshifumi Hibi, Ken Takeuchi, Fernando Magro, Yoorim An, Dong-Hyeon Kim, SangWook Yoon, Walter Reinisch

Before the COVID-19 pandemic

- CT-P13 SC is the first SC formulation of infliximab that received regulatory approval
- SC infliximab may be recognised as a biobetter, based on:
  - ✓ Enhanced clinical outcomes (e.g. improved PK)
  - ✓ Increased convenience

SC infliximab (CT-P13 SC)

During the acute COVID-19 pandemic

- Patients successfully switch from IV to SC infliximab, with:
  - ✓ Clinical benefits
  - ✓ High levels of patient satisfaction
- SC infliximab enables self-administration and facilitates transition from hospital- to home-based care, which:
  - ✓ Reduces nosocomial SARS-CoV-2 exposure
  - ✓ Offers potential pharmacoeconomic benefits





During the chronic threat of COVID-19 and beyond

- Telemedicine has been pushed to the forefront during the pandemic
  - ✓ SC infliximab is compatible with future healthcare systems
- Patients, physicians, and healthcare systems will benefit from the uptake of SC infliximab

COVID-19, coronavirus disease 2019; IV, intravenous; PK, pharmacokinetics; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SC, subcutaneous.

The graphical abstract represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online.

 https://doi.org/10.1007/s12325-021-01990-6